VivoSeq
Cardiovascular

Acute Myocardial Infarction

185

Pipeline Programs↗

31

Active Trials↗

69

Companies Involved↗

Acute Myocardial Infarction is a highly competitive landscape with 185 programs across 69 companies. The most active players are Sclnow Biotechnology Co., Ltd., Beijing Northland Biotech. Co., Ltd., CSL Behring. 72 therapies are approved with 46 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

79/100

Pipeline Velocity

30/100

Mech. Concentration

4/100

Completion Rate

90/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Sclnow Biotechnology Co., Ltd.

1 program

Phase 1B

Beijing Northland Biotech. Co., Ltd.

2 programs

Phase 2CSL Behring logo

CSL Behring

1 program

Phase 2R

RegeneRx Biopharmaceuticals, Inc.

1 program

Phase 2Q

Quantum Genomics SA

1 program

Phase 2C

Cytori Therapeutics

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical25

Tenecteplase

Roche

Nicorandil

Merck & Co.

Valsartan

Novartis

Acetaminophen

Kenvue Brands

Alteplase

Roche

Phase 14

Intensive Insulin Therapy

Northwestern University

Provacel

Mesoblast, Ltd.

FAP Immunosuppressive CAR-DC

Second Affiliated Hospital, School of Medicine, Zhejiang University

Metoprolol- Toprol XL

AstraZeneca

Phase 238

Tocilizumab

Roche

Epoetin Beta

Roche

Melatonin

Neurim Pharmaceuticals Ltd.

Sodium Nitrite

Hope Pharmaceuticals

Deferiprone

Chiesi Farmaceutici S.p.A.

Phase 346

Anakinra

Swedish Orphan Biovitrum

Abciximab

Boehringer Ingelheim

Adenosine

Astellas

Dapagliflozin

AstraZeneca

Furosemide

Validus Pharmaceuticals

Approved72

Vericiguat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Inclisiran

Novartis

Clopidogrel

Sanofi

Cangrelor

Chiesi Farmaceutici S.p.A.

Eptifibatide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Analysis

Modality Breakdown

89%

Small molecule

179 of 202 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody84%Cell therapy63%Protein / enzyme52%Peptide31%RNA therapy1<1%

Small molecule leads; the ring shows all 202 classified programs, each share of the total. Modality classified for 100% of 217 pipeline programs.

Analysis

Trial Status

195

clinical trials

Completed121 · 62%
Unknown status29 · 15%
Recruiting15 · 8%
Not yet recruiting9 · 5%
Terminated8 · 4%
Active, not recruiting7 · 4%
Other6 · 3%

Clinical Trials

Trial Activity

195 trials

Very Early PCSK9 Inhibition for Acute Myocardial Infarction
Recruiting·SShanghai Zhongshan Hospital·N/A·NCT07208006·1,518 enrolled
Metformin and Prevention of Cardiovascular Events in Patients With Acute Myocardial Infarction and Prediabetes (MIMET)
Recruiting·KKarolinska Institutet·Phase 3·NCT05182970·5,160 enrolled
Interleukin-1 Blockade in Acute Myocardial Infarction to Prevent Heart Failure
Recruiting·VVirginia Commonwealth University·Phase 2·NCT05177822·84 enrolled
The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT07381803·2,804 enrolled
Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients
Recruiting·—·Phase 2·NCT05604131·89 enrolled
SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study
Recruiting·—·N/A·NCT05770687·1,000 enrolled
DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction
Recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05764057·450 enrolled
Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction
Recruiting·—·Phase 4·NCT05168462·776 enrolled
Stratified Medicine of Eplerenone in Acute Myocardial Infarction or Injury and no Obstructive Coronary Arteries.
Recruiting·NNHS National Waiting Times Centre Board·Phase 2·NCT05198791·400 enrolled
Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction
Recruiting·KKarolinska Institutet·Phase 4·NCT06515730·212 enrolled
STunning in Acute Myocardial Infarction - BAS
Recruiting·—·Phase 4·NCT06562582·120 enrolled
Long-term Beta-blocker Therapy After Acute Myocardial Infarction
Recruiting·SSamsung Medical Center·Phase 4·NCT04769362·2,540 enrolled
Ezetimibe Utilization Early After Acute Myocardial Infarction, "EzAMI Trial"
Recruiting·—·N/A·NCT04701242·500 enrolled
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
Recruiting·EECRI bv·Phase 3·NCT07276282·332 enrolled
Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
Recruiting·SSamsung Medical Center·Phase 4·NCT04899479·200 enrolled
Page 1 of 13

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)